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Background: Select trials of fructose overfeeding have been used to implicate fructose
as a driver of cardiometabolic risk.
Objective: We examined temporal trends of fructose dose in human controlled feeding
trials of fructose and cardiometabolic risk.
Methods: We combined studies from eight meta-analyses on fructose and car-
diometabolic risk to assess the average fructose dose used in these trials. Two types of
trials were identified: (1) substitution trials, in which energy from fructose was exchanged
with equal energy from other carbohydrates and (2) addition trials, in which energy from
fructose supplemented a diet compared to the diet alone.
Results: We included 64 substitution trials and 16 addition trials. The weighted aver-
age fructose dose in substitution trials was 101.7 g/day (95% CI: 98.4–105.1 g/day),
and the weighted average fructose dose in addition trials was 187.3 g/day (95% CI:
181.4–192.9 g/day).
Conclusion: Average fructose dose in substitution and addition trials greatly exceed
national levels of reported fructose intake (491.0 g/day) (NHANES 1977–2004). Future
trials using fructose doses at real world levels are needed.
Keywords: fructose, HFCS, dose, cardiometabolic risk, meta-analysis
Introduction
With the increase in high-fructose corn syrup (HFCS) consumption since 1970s, there has been
rising interest in the role of sugars toward the development of cardiometabolic diseases (1).
Particular attention has focused on the “fructose hypothesis,” which suggests that the metabolic
and endocrine responses unique to fructose are the main drivers in the etiology of obesity,
diabetes, and cardiometabolic risk (2, 3). While this perspective is well supported by lower
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16673 reports identified:
Glycemic Control: 4838 (through February 20, 2014)
Uric Acid: 375 (through August 19, 2011)
Blood Pressure: 319 (through January 9, 2012)
Body Weight (fructose):1984 (through November 18, 2011)
Body Weight (fructose-containing SSBs): 4732 (through May 23 2014)
Post Prandial Triglycerides: 1259 (through September 3, 2013)
Fasting Lipids: 1729 (through July 17, 2014)
NAFLD: 1437 (through September 3, 2013)
617 reports reviewed in full:
Glycemic Control: 60
Uric Acid: 35
Blood Pressure: 16 
Body Weight (fructose): 81
Body Weight (fructose-containing SSBs): 117
Post Prandial Triglycerides: 48
Fasting Lipids: 167
NAFLD: 93
203 reports included in meta-analyses (267 Trials):
Glycemic Control: 41 (58 trials, n=1025)
Uric Acid: 16 (21 trials, n=425)
Blood Pressure: 11 (15 trials, n=376)
Body Weight (fructose all forms): 32 (41 trials, n=756)
Body Weight (fructose-containing SSB): 43 (46 trials, n=3440)
Post Prandial Triglycerides: 11 (32 trials, n=322)
Fasting Lipids: 41 (57 trials, n=1007)
NAFLD: 8 (13 trials, n=260)
55 reports included in final analysis (80 Trials):
64 Substitution trials, n=1235
16 Addition trials, n=197
16056 duplicate and irrelevant reports excluded 
based on title/ abstract review
414 irrelevant reports excluded based on full 
article review
148 duplicate reports excluded
FIGURE 1 | Systematic search and selection strategy. Flow of
literature for eight separate searches of the effect of fructose on: glycemic
control (fasting blood glucose, fasting blood insulin, HbA1c), uric acid,
blood pressure, body weight (fructose), body weight (fructose-containing
sugars-sweetened beverages, post prandial triglycerides, fasting lipids,
and NAFLD.
quality evidence from ecological studies (4) and animal models
(5–7), it is not well supported by the highest level of evidence from
controlled trials in humans (8–13).
A main limitation of these trials has been the use of
extreme levels of fructose feeding not representative of real
world conditions. The present analysis aims to quantify the
dose of fructose used in trials assessing the effects of fruc-
tose and cardiometabolic risk, and compare it to national
levels of fructose consumption in the United States at the
average and 95th percentile levels of intake based on the
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TABLE 1 | Characteristics of trials investigating the effect of fructose on cardiometabolic risk.
Reference Subjectsa Age (years) Setting Design Feeding
controlb
Randomization Fructose
dosec
Fructose
formd
Comparator Diete Follow-up MQSf Energy
Balance
Funding
sourcesg
SUBSTITUTION TRIALS
(15) 5 HTG
(3M:2F) 4 N
(3M:1F)
42.814.2 IP/OP,
Israel
C Met No 300g/d
(55% E)
Mixed Starch 77:05:18 24d 7 Neutral Agency
(16)
(Study 1)
3 HTG 190 IP,
Australia
C Met No 255 g/d
(50–52% E)
Mixed Glucose 77:09:14 1wk 6 Neutral Agency
(16)
(Study 2)
2 HTG 190 IP,
Australia
C Met No 255 g/d
(52–55% E)
Mixed Glucose 77:09:14 1wk 6 Neutral Agency
(17) 16 DM1 10 (2–16) OP,
Finland
C Supp No 40 g/d
(20% E)
Mixed Starch 45:35:20 1wk 4 Neutral Industry
(18) 10 type 4
HTG (5 DM2)
53.5
(26-67)
IP,
Finland
C Met Yes 77.5 g/d
(17% E)
Liquid Starch,
sucrose
45:35:20 10–20d 6 Neutral Agency
(19) 10 DM1
(5M:5F)
25.5
(19–70)
IP,
Finland
C Met No 75g/d
(15% E)
Mixed Starch 40:40:20 10d 7 Neutral Agency
(20) 12 N (8M:4F) (20–26) IP,
Germany
C Met No 162g/d
(33% E)
Liquid Glucose,
sucrose
90:00:10 10d 7 Neutral –
(21) 68 N (13–55) OP,
Finland
P Dietary
Advice
No 70g/d
(14% E)
Mixed Sucrose - 72wks 5 Neutral –
(22) (LC) 4 HTG
(4M:0F)
488.8 IP, USA C Met No 39.5 g/d
(9% E)
Liquid D-Maltose 45:40:15 2wks 7 Neutral Agency and
industry
(22) (HC) 4 HTG
(4M:0F)
488.8 IP, USA C Met No 122 g/d
(17%E)
Liquid D-Maltose 85:00:15 2wks 4 Neutral Agency and
industry
(22) 2 DM2
(2M:0F)
411.4 IP, USA C Met No 40 g/d
(9% E)
Liquid D-Maltose 45:40:15 2 wks 7 Neutral Agency and
industry
(23) 15 N (21–35) OP,
Denmark
P Supp Yes +250 g/d
(+50% E)
Liquid Glucose 44:38:18 1wk 6 Positive Agency and
industry
(24) 16 type 4
HTG
57 (38–80) OP,
Poland
C Supp No 80g/d Liquid Starch 45:50:15 28d 7 Neutral –
(25) – N
(HF)
12 N
(12M:0F)
39.88.3 IP/OP,
USA
C Met No 101.3 g/d
(15% E)
Solid Starch 43:42:15 5wks 8 Neutral –
(25) – N
(LF)
12 N
(12M:0F)
39.88.3 IP/OP,
USA
C Met No 50.6 g/d
(7.5% E)
Solid Starch 43:42:15 5wks 8 Neutral –
(25) – HI
(HF)
12 HI
(12M:0F)
39.57.3 IP/OP,
USA
C Met No 101.3 g/d
(15% E)
Solid Starch 43:42:15 5wks 8 Neutral –
(25) – HI
(LF)
12 HI
(12M:0F)
39.57.3 IP/OP,
USA
C Met No 50.6 g/d
(7.5% E)
Solid Starch 43:42:15 5wks 8 Neutral –
(26) 8 N (4M:4F) 26.7
(20–32)
IP/OP,
USA
C Met Yes 79 g/d
(14% E)
Liquid Sucrose 43:40:17 2wks 8 Neutral Agency
(27) 11 N (4M:7F) 39.511.4 IP/OP,
USA
C Met No 81 g/d
(13.2% E)
Mixed Sucrose 55:30:15 2wks 7 Neutral Agency and
industry
(28) 12 DM1
(6M:6F) 12
DM2 (5M:7F)
23 (15–32)
62 (36–80)
OP, USA C Met Yes 137 g/d
(21% E)
Mixed Starch 55:30:15 8d 8 Neutral Industry
(Continued)
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TABLE 1 | Continued
Reference Subjectsa Age (years) Setting Design Feeding
controlb
Randomization Fructose
dosec
Fructose
formd
Comparator Diete Follow-up MQSf Energy
Balance
Funding
sourcesg
(29) 7 DM2
(3M:4F)
50.98.4 IP/OP,
USA
C Met No 98 g/d
(13.2% E)
Mixed Sucrose 55:30:15 2wks 7 Neutral Agency and
industry
(30)
EXP 1
23 OW/OB 22.2 OP,
France
P Met Yes 36 g/d
(25%E)
Liquid Glucose,
galactose
25:50:25 2wks 8 Negative Industry
(30)
EXP 2
18 OW/OB 22.2 OP,
France
P Met Yes 36 g/d
(25%E)
Liquid Glucose,
galactose
25:50:25 2wks 8 Negative Industry
(31) 10 DM2 64.4
(54–71)
OP,
Ireland
C Supp No 55g/d
(11.6% E)
Liquid Starch 42:38:20 4wks 7 Neutral Industry
(32) 18 DM2
(3M:15F)
573.0 OP, USA P Supp Yes 60 g/d
(10% E)
Mixed Starch 50:35:15 12wks 8 Neutral Agency and
industry
(33) 8 DM2
(5M:3F)
406.9 OP,
France
C Supp Yes 30 g/d
(8% E)
Mixed Starch 50:30:20 8wks 8 Neutral Agency and
industry
(34) –
NGT
9 N (3M:6F) 48 OP, USA C Supp No 79 g/d
(15% E)
Mixed Glucose 53:32:16 4wks 8 Neutral –
(34) – IGT 9 IGT
(3M:6F)
53 OP, USA C Supp No 64 g/d
(15% E)
Mixed Glucose 53:32:16 4wks 8 Neutral –
(35) 14 DM2
(14M:0F)
604
(54–71)
IP/OP,
USA
C Met/Supp No 55 g/d
(12% E)
Mixed Starch 53:27:20 23wks 8 Neutral Agency and
industry
(36) 13 DM2
(5M:8F)
5411 OP, USA C Supp Yes 60 g/d
(7.5% E)
Mixed Starch 50:35:15 26wks 8 Neutral Agency and
industry
(37) 10 IR (10M:
0F)
47 IP, USA C Met No 167g/d
(20% E)
Solid Starch 51:36:13 5wks 4 Neutral –
(38) 8 DM2
(4M:4F)
5511.2 IP, USA P Met No 100 g/d
(13% E)
Mixed Sucrose 55:30:15 12wks 6 Neutral Agency and
industry
(67) 14 DM1, 6
DM2
46.913.1 OP,
France
P Supp Yes 25 g/d
(5% E)
Mixed Starch,
sucrose
55:30:15 52wks 7 Neutral Agency and
industry
(68) 6 DM2
(4M:2F)
53.710.2 IP, USA C Met No 100 g/d
(13% E)
Mixed Sucrose 55:30:15 100d 4 Neutral Agency and
industry
(39) 6 DM1
(3M:3F) 12
DM2 (4M:8F)
23 (18–34)
62 (40–72)
OP, USA C Met Yes 120 g/d
(20% E)
Mixed Starch 55:30:15 4wks 8 Neutral Agency
(40) 14 N (7M:7F) 34 (19–60) IP/OP,
USA
C Met Yes 120 g/d
(20% E)
Mixed Starch 55:30:15 4wks 8 Neutral Agency
(41) 10 DM2
(4M:6F)
619.5 IP,
Finland
C Met Yes 55 g/d
(10% E)
Liquid Starch 50:30:20 4wks 9 Neutral Agency
(42) 16 DM2
(7M:9F)
54.29.2 OP, Brazil C Supp No 63.2 g/d
(20% E)
Liquid Starch,
sucrose
55:30:15 4wks 7 Neutral Industry
(43) 24 N
(12M:12F)
41.320.0 OP, USA C Met Yes 85 g/d
(17% E)
Mixed Glucose 55:30:15 6wks 9 Neutral Agency
(44) – P1 24 N
(12M:12F)
14.61.2 OP, USA P Met Yes 64.19 g/d
(12% E)
Mixed Starch 30:55:15 1wk 9 Neutral Agency and
industry
(44) – P2 12 N (6M:6F) 14.81.32 OP, USA C Met Yes 151.32 g/d
(24% E)
Mixed Starch 60:25:15 1wk 9 Neutral Agency and
industry
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TABLE 1 | Continued
Reference Subjectsa Age (years) Setting Design Feeding
controlb
Randomization Fructose
dosec
Fructose
formd
Comparator Diete Follow-up MQSf Energy
Balance
Funding
sourcesg
(45) 12 N (6M:6F) 15.30.8 OP, USA C Met Yes 128.5g/d
(40% E)
Mixed Starch 60:25:15 8 d 9 Neutral Agency and
industry
(46) 25 DM2 62.310.1 OP, Israel P Supp Yes 22.5 g/d
(4.5% E)
Liquid Starch – 12wks 5 Neutral –
(47) 6 OB (3M:3F) 15.21.22 OP, USA C Met Yes 149.1 g/d
(24% E)
Mixed Starch 60:25:15 1wk 9 Neutral Agency and
industry
(48) 7 OW/OB
(0M:7F)
(50–72) IP, USA C Met No 125 g/d
(25% E)
Liquid Starch 55:30:15 10wks 7 Neutral Agency
(49) 32 OW/OB
(16M:16F)
53 IP/OP,
USA
P Met/Supp No 182 g/d
(+ 25% E)
Liquid Glucose 55:30:15 10wks 6 Positive Agency
(50) 11 N
(11M:0F)
24.62.0 OP,
Switzer-
land
C Met Yes +213g/d
(+ 35% E)
Liquid Glucose 55:30:15 1wk 8 Positive Agency
(51) (LF) 29 N
(29M:0F)
26.36.6 OP,
Switzer-
land
C Supp Yes 40 g/d
(7% E)
Liquid Glucose,
starch
51:14:35 3wks 9 Positive Agency
(51) (HF) 29 N
(29M:0F)
26.36.6 OP,
Switzer-
land
C Supp Yes 80 g/d
(13% E)
Liquid Glucose,
sucrose
55:13:32 3wks 9 Positive Agency
(52) 131 OW/OB
(29M:102F)
38.88.8 OP,
Mexico
P Dietary
advice
Yes 60 g/d
(13% E)
Solid Starch 55:30:15 6wks 9 Negative Agency
(53) 20 N
(12M:8F)
30.58.93 OP,
Germany
P Supp Yes +150g/d
(+ 22% E)
Liquid Glucose 50:35:15 4wks 7 Positive Agency
(54) 32 OW/OB
(16M:16F)
548 IP/OP,
USA
P Met/Supp No +182g/d
(+ 25% E)
Liquid Glucose 55:30:15 10wks 6 Positive Agency
(54) 48 N
(27M:21F)
27.67.1 IP/OP,
USA
P Met/Supp No +168g/d
(+ 25% E)
Liquid Glucose
HFCS
55:30:15 2wks 6 Positive Agency
(55) 28 CKD
(17M:11F)
5915 OP,
Poland
C Dietary
advice
No 56 g/d
(10% E)
Mixed Starch 55:30:15 6wks 8 Neutral Agency
(56) 31 OW/OB
(16M:15F)
53.78.1 IP/OP,
USA
P Met/Supp No +182g/d
(+25% E)
Liquid Glucose 55:30:15 10wks 6 Positive Agency
(57) 9 N (9M:0F) 22.71.8 OP,
Switzer-
land
C Supp Yes 80 g/d
(+13% E)
Liquid Glucose
sucrose
55:31:14 3wks 9 Positive Agency
(58) –
(NEB)
32 OW/OB
(32M:0F)
33.910.0 OP, UK P Met/Supp Yes 204 g/d
(25% E)
Liquid Glucose 55:30:15 8wks 10 Neutral Agency
(58) –
(PEB)
32 OW/OB
(32M:0F)
33.910.0 OP, UK P Met/Supp Yes +204g/d
(+25% E)
Liquid Glucose 55:30:15 8wks 10 Positive Agency
(59) 28 N
(28M:0F)
22.51.6 OP,
Switzer-
land
P Supp Yes 212 g/d
(+24% E)
Liquid Glucose – 7 d 9 Positive Agency
(60) 9 N (4M:5F) 20.92 OP, USA C Met Yes 129 g/d
(25% E)
Liquid Glucose 50:34:16 8d 8 –
(Continued)
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TABLE 1 | Continued
Reference Subjectsa Age (years) Setting Design Feeding
controlb
Randomization Fructose
dosec
Fructose
formd
Comparator Diete Follow-up MQSf Energy
Balance
Funding
sourcesg
(61) 40 N
(40M:20F)
17.91.9 OP, USA C Supp Yes 50 g/d
(+10% E)
Liquid Glucose – 2wks 7 Positive Agency
(62) 21 OW
(11M:10F)
13.52.5 OP, USA P Supp Yes +99g/d
(+19.8% E)
Liquid Glucose – 4wks 5 Neutral Agency
(63) 73 OW
(0M:73F)
39.78.6 OP,
Denmark
P Supp Yes +60g/d
(+13.6% E)
Liquid Glucose 45:34:21 4wks 9 Positive Agency
(61) 7 OW
(3M:4F)
180.4 OP, USA C Supp Yes +50g/d
(+6.7% E)
Liquid Glucose – 2wks 8 Positive Agency
ADDITION TRIALS
(23) 8 N 21–35 OP,
Denmark
C Supp No 250 g/d
(+50%E)
Liquid Diet alone 44:38:18 1wk 5 Positive Agency and
industry
(30) EXP
2
14 OW/OB 22.2 OP,
France
P Met Yes +100g/d
(+97% E)
Liquid Diet alone 0:35:65 2wks 8 Negative Industry
(64) 7 N (7M:0F) 24.703.44 OP,
Switzer-
land
C Supp No +104g/d
(+18% E)
Liquid Diet alone 55:30:15 4wks 7 Positive Agency
(65) (N) 8 N (8M:0F) 24.54.5 OP,
Switzer-
land
C Supp Yes 213 g/d
(+35% E)
Liquid Diet alone 55:30:15 7d 9 Positive Agency and
industry
(65) 16 OFFDM2
(16M:0F)
24.75.2 OP,
Switzer-
land
C Supp Yes 220 g/d
(+35% E)
Liquid Diet alone 55:30:15 1wk 8 Positive Agency and
industry
(49) 17 OW/OB
(9M:8F)
52.59.2 IP/OP,
USA
C Met/Supp No 182 g/d
(25% E)
Liquid Diet alone 55:30:15 10wks 6 Positive Agency
(50) 11 N
(11M:0F)
24.6 OP,
Switzer-
land
C Met/Supp Yes 213 g/d
(+35%E)
Liquid Diet alone 55:30:15 7d 8 Positive Agency
(66) 8 N (8M:0F) 24.83.2 OP,
Switzer-
land
C Supp No +212g/d
(+35% E)
Liquid Diet alone 55:30:15 1wk 6 Positive Agency
(53) 10 N (7M:3F) 32.89.3 OP,
Germany
C Supp No +150g/d
(+22% E)
Liquid Diet alone 50:35:15 4wks 6 Positive Agency
(54) 17 OW/OB
(9M:8F)
52.59.3 IP/OP,
USA
C Met/Supp No +182g/d
(+25% E)
Liquid Diet alone 55:30:15 10wks 5 Positive Agency
(54) 16 N (9M:7F) 28.06.8 IP/OP,
USA
C Met/Supp No +168g/d
(+25% E)
Liquid Diet alone 55:30:15 2wks 6 Positive Agency
(56) 16 OW/OB
(9M:7F)
52.59.3 IP/OP,
USA
C Met/Supp No +182g/d
(+25% E)
Liquid Diet alone 55:30:15 10wks 5 Positive Agency
(58) 15 OW/OB
(15M:0F)
35.011.0 OP, UK C Supp No +203g/d
(+25% E)
Liquid Diet alone 55:30:15 2wks 8 Positive Agency
(59) (F1.5) 7 N (7M:0F) 22.51.6 OP,
Switzer-
land
C Supp Yes +104g/d
(+14%E)
Liquid Diet alone – 7 d 9 Positive Agency
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National Health and Nutrition Examination Survey (NHANES
1977–2004) (14).
Materials and Methods
We collated studies previously identified in a series of meta-
analyses and systematic reviews of the effects of fructose on
various cardiometabbolic endpoints (8–13). We included con-
trolled dietary trials across all populations investigating the effect
of fructose on fasting blood lipids (Chiavaroli et al., unpub-
lished study), postprandial triglycerides (13), blood pressure (9),
glycemic control (Cozma et al., unpublished study), uric acid (11),
non-alcoholic fatty liver disease (NAFLD) (12), body weight using
mixed forms of fructose (solid, liquid, mixed) (10), and body
weight from fructose-containing sugars-sweetened beverages only
(Choo et al., unpublished study). Trials lasting <7 days, using
intravenous administration or possessing unsuitable endpoints or
comparators were excluded. Two types of trials were identified for
the purposes of this analysis-substitution trials, in which fructose
was exchanged for equal amounts of energy from other carbohy-
drates, or addition trials, inwhich a control diet was supplemented
with additional energy from fructose compared to the control diet
alone without the excess energy. Duplicate studies between meta-
analyses were removed, and fructose dose data were extracted
from each study when available and reported in grams per day.
A weighted average fructose dose used across all studies was
calculated according to the sample size of each trial, and reported
as a mean and 95% confidence interval.
Results
The search and selection process can be found in Figure 1. A
total of 16,673 reports were identified between all meta-analyses,
and 203 reports (267 trials) were included after excluding reports
based on title and abstract. After combining eligible trials and
removal of duplicates from the meta-analyses, 64 substitution
trials (1235 participants) and 16 addition trials (197 participants)
were included in this analysis.
Trial Characteristics
Table 1 provides a detailed summary of trial characteristics. There
were 64 substitution trials involving 1235 participants (15–63) and
16 addition trials involving 197 participants (23, 30, 49, 50, 53, 54,
56, 58, 59, 64–66). Sample sizes of substitution and addition trials
tended to be small [median number of participants, 12.5 (IQR:
9–24) and 12.5 (IQR: 8–16) for substitution and addition trials,
respectively]. A majority of trials used a crossover design (69 and
94% of substitution and addition trials, respectively). Participants
in substitution trials tended to be middle aged males and females
[55%males;median age, 39.5 years (IQR: 23.4–53 years)], whereas
participants in addition trials tended to be younger males [81%
males; median age, 24.7 years (IQR: 23.5–33.9 years)]. Study dura-
tion was relatively short in both types of trials [median, 4 weeks
(IQR: 2–6weeks) and median 1.5 weeks, (IQR: 1–4weeks) in sub-
stitution and addition trials, respectively] and predominantly took
place in the United States for substitution trials and Europe for
addition trials under an outpatient setting. Comparators in substi-
tution trials included starch (30%), glucose (26%), sucrose (8%),
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FIGURE 2 | Trends of fructose dose in substitution trials. Individual
trials are plotted based on date of publication and fructose dose used.
Sample size of each trial is represented by the size of its respective circle.
The weighted average fructose dose across all substitution trials was
101.7 g/day (95% CI: 98.4–105.1 g/day), indicated by the solid and
dashed blue lines.
-maltose (3%), galactose (2%), and HFCS (1%) and comparators
in all addition trials were diet alone.
Fructose Dose
Figures 2 and 3 show trends of fructose dose in substitution
and addition trials plotted against the average and 95th per-
centile intakes of fructose in the United States (49 1.0 and
87 4.0 g/day, respectively). Substitution trials were conducted
from 1966 to 2014 withmost conducted during 1980s and a recent
resurgence in 2010s, while the addition trials were conducted
from 1980 to 2013 with most conducted after the mid 2000s.
The weighted average fructose dose in substitution trials was
two times higher than reported average population intake levels
[101.7 g/day (95% CI: 98.4–105.1 g/day)], whereas the weighted
average fructose dose in the addition trials was much greater, at
~3.7 times the amount of the reported average population intake
levels [187.3 g/day (95% CI: 181.4–192.9 g/day)].
Discussion
This analysis, which combined the trials identified from eight
meta-analyses, aimed to examine the trends of fructose dose in
controlled dietary trials assessing the effects of fructose on various
cardiometabolic outcomes. We identified 64 substitution trials, in
which fructose was provided in isocaloric substitution for other
carbohydrate sources (usually starch), and 16 addition trials, in
which fructose supplemented diets with excess energy compared
to the same diets without the excess energy. The average weighted
fructose dose was 101.7 g/day (95% CI: 98.4–105.1 g/day) in sub-
stitution trials from 1966 to 2014, whereas the average weighted
fructose dose was nearly twice as high at 187.3 g/day (95% CI:
181.4–192.9 g/day) in the 16 addition trials from 1980 to 2013.
There were differences observed in the temporal trends
between substitution and addition trials. Most substitution trials
were conducted in 1980s with a resurgence that followed in 2010s.
The reason for this pattern is unclear. A growing interest in fruc-
tose trials early onmayhave reflected the initial interest in fructose
as a potentially beneficial alternative sweetener (69–71). By con-
trolling for energy, substitution trials provided a rigorous study
design,which allowed for the assessment ofwhether fructose had a
unique set of metabolic or endocrine responses beyond its energy
across a wide dose range. The emergence of the addition trials in
2000s may have grown out of the consistent lack of effect or even
the benefit (glycemic control) seen in the substitution trials (8)
and the concern stimulated by the ecological analysis of Bray et al.
(4) linking fructose from HFCS with the epidemic of overweight
and obesity. The recent resurgence of substitution trials in 2010s
appears to have been to reconcile the role of energy from that
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FIGURE 3 | Trends of fructose dose in addition trials. Individual
trials are plotted based on date of publication and fructose dose used.
Sample size of each trial is represented by the size of its respective
circle. The weighted average fructose dose across all addition trials was
187.3 g/day (95% CI: 181.4–192.9 g/day), indicated by the solid and
dashed red lines.
of fructose in the addition trials. To test whether overfeeding
of fructose differs from overfeeding of any other macronutrient
(usually glucose or starch), these trials have compared fructose
with other sources of carbohydrate under conditions of matched
overfeeding.
Irrespective of any control for energy, the levels of intake
observed in the available trials has been well beyond popula-
tion levels of consumption. Compared to levels of reported fruc-
tose intake assessed by the National Health and Examination
Survey in the United States (NHANES 1977–2004), the doses
used in both the substitution and the addition trials exceeded
the average and 95th percentile levels of fructose consump-
tion (49 1.0 and 87 4.0 g/day, respectively). Furthermore, all
addition trials used doses of fructose above the 95th percentile
of reported intake, with the weighted average dose more than
double that amount. While the present analysis suggests that
these trials using supraphysiological doses of fructose feeding
are not representative of levels normally consumed in the diet,
the important caveat remains that underreporting from national
population intake surveys, such as NHANES, may underes-
timate the actual amount of fructose consumed (72). How-
ever, taking into consideration the potential for underreporting
when interpreting calculated trial means compared to reported
population means, if an estimated level of 50% underreport-
ing were present (average and 95th percentile fructose intake
of 100 and 172 g/day, respectively), the fructose dose in sub-
stitution trials would reach levels representative of true dietary
intake [101.7 g/day (95%CI: 98.4–105.1 g/day)], while supraphys-
iological doses of fructose in addition trials would still persist
[187.3 g/day (95% CI: 181.4–192.9 g/day)]. Another important
consideration is that fructose consumption has been changing
with time in NHANES. HFCS (a main proxy for fructose con-
sumption) availability has been declining since it peaked in 1999
(73). Variability of fructose consumption over time should be
taken into consideration when predicting the true population
average intake.
The implications of our findings suggest a potential lack of
ecological validity when drawing conclusions from addition
trials using unrealistically high doses of fructose. As with
the excess consumption of any macronutrient, an adverse
effect on cardiometabolic risk factors may be irrelevant
under levels of normal dietary consumption and lead to
unnecessary concern and confusion regarding the safety of
fructose. Two trial designs have helped to clarify whether
adverse effects relate to excess energy (either from fructose
or any macronutrient in general) or specific metabolic and
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endocrine properties inherent to fructose itself. In a series of
systematic reviews andmeta-analyses of controlled trials to deter-
mine the effect of fructose on various cardiometabolic outcomes,
a consistent signal for harm has only been shown in the addi-
tion trials (8–10, 12, 13). Substitution trials have failed to show
differences in body weight (10), fasting triglycerides (74), post-
prandial triglycerides (13), uric acid (9), glucose, insulin (8),
or markers of NAFLD (12) with improvements seen in blood
pressure (9) and glycemic control (8, 75). These findings hold
even under conditions of overfeeding as long as the excess energy
is matched. The one exception may be for an effect on fast-
ing triglycerides at a high dose threshold as seen in some sub-
group analyses (76, 77). Taken together, these findings suggest
that fructose appears to be a determinant of cardiometabolic
risk only in as much as it contributes to excess energy in
the diet.
Conclusion
Most trials on fructose and cardiometabolic risk have used
doses of fructose well beyond reported population levels of
intake. While such high doses may be useful for determining
a cause-effect relationship, replication of these studies using
fructose doses closer to dietary levels are warranted and could
help to establish a threshold beyond which excess energy
from fructose demonstrate a signal for harm under real world
conditions.
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